2023 half year results and business update
Category: TG6050-en
Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer
First patient dosed in Phase I trial evaluating TG6050 15
Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR
Preclinical results showing TG6050 induces tumor regression by activating innate and adaptive immune responses 15
TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses
JB. Marchand et al.AACR 2023Download the poster herePoster Presentation
Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
Transgene to present multiple posters highlighting the potential of its exciting immunotherapy pipeline at AACR2023 15
Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
Transgene recieves approval to start a Phase I trial of TG6050 15
